The Royal Melbourne Hospital in Australia is running an interventional study of a low-carbohydrate/ketogenic diet combined with ketone supplementation in adults with ADPKD. The trial is led by Professor Karen Dwyer, Director of Nephrology at the Royal Melbourne Hospital and Professor of Nephrology at the University of Melbourne, and is registered on the Australian New Zealand Clinical Trials Registry as ACTRN12625000785404.
Participants follow a structured low-carb/ketogenic program delivered through the Defeat Diabetes app, which provides meal plans, education and behavioural support. They also take KetoCitra, about 10g twice daily, and wear continuous glucose monitors during the first and third months, with the research team using the glucose data to give personalised feedback.
The primary outcomes are tolerability, quality of life (AQOL-8D) and kidney function (eGFR) at three months. Secondary outcomes include cystatin C, fasting glucose, insulin resistance (HOMA-IR), HbA1c, glucose variability, lipids, uric acid, liver function and proteinuria.
This brings the number of clinical trials of ketogenic interventions in ADPKD to five worldwide, alongside Juntendo University, Cleveland Clinic, Ohio State and the Danish KETO-CKD trial. Santa Barbara Nutrients lists the study as recruiting and enrolling up to 50 participants; the registry record has not been updated since July 2025.